Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma

Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma

Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 155(2014), 2 vom: 22. Dez., Seite 176-87
1. Verfasser: Berkowitz, Jonathan L (VerfasserIn)
Weitere Verfasser: Janik, John E, Stewart, Donn M, Jaffe, Elaine S, Stetler-Stevenson, Maryalice, Shih, Joanna H, Fleisher, Thomas A, Turner, Maria, Urquhart, Nicole E, Wharfe, Gilian H, Figg, William D, Peer, Cody J, Goldman, Carolyn K, Waldmann, Thomas A, Morris, John C
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2014
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial, Phase I Clinical Trial, Phase II Journal Article Research Support, N.I.H., Intramural Adult T-cell leukemia/lymphoma Daclizumab Human T-cell leukemia virus 1 (HTLV-1) associated ATL Interleukin-2 receptor alpha Monoclonal antibody Antibodies, Monoclonal, Humanized mehr... Antineoplastic Agents Immunoglobulin G Interleukin-2 Receptor alpha Subunit CUJ2MVI71Y
LEADER 01000caa a22002652 4500
001 NLM242333427
003 DE-627
005 20240511232319.0
007 cr uuu---uuuuu
008 231224s2014 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2014.09.012  |2 doi 
028 5 2 |a pubmed24n1404.xml 
035 |a (DE-627)NLM242333427 
035 |a (NLM)25267440 
035 |a (PII)S1521-6616(14)00223-X 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Berkowitz, Jonathan L  |e verfasserin  |4 aut 
245 1 0 |a Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma 
264 1 |c 2014 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 19.02.2015 
500 |a Date Revised 11.05.2024 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Published by Elsevier Inc. 
520 |a Interleukin-2 receptor α chain (CD25) is overexpressed in human T-cell leukemia virus 1 associated adult T-cell leukemia/lymphoma (ATL). Daclizumab a humanized monoclonal antibody blocks IL-2 binding by recognizing the interleukin-2 receptor α chain (CD25). We conducted a phase I/II trial of daclizumab in 34 patients with ATL. Saturation of surface CD25 on circulating ATL cells was achieved at all doses; however saturation on ATL cells in lymph nodes required 8 mg/kg. Up to 8 mg/kg of daclizumab administered every 3 weeks was well tolerated. No responses were observed in 18 patients with acute or lymphoma ATL; however, 6 partial responses were observed in 16 chronic and smoldering ATL patients. The pharmacokinetics/pharmacodynamics of daclizumab suggest that high-dose daclizumab would be more effective than low-dose daclizumab in treatment of lymphoid malignancies and autoimmune diseases (e.g., multiple sclerosis) since high-dose daclizumab is required to saturate IL-2R alpha in extravascular sites 
650 4 |a Clinical Trial, Phase I 
650 4 |a Clinical Trial, Phase II 
650 4 |a Journal Article 
650 4 |a Research Support, N.I.H., Intramural 
650 4 |a Adult T-cell leukemia/lymphoma 
650 4 |a Daclizumab 
650 4 |a Human T-cell leukemia virus 1 (HTLV-1) associated ATL 
650 4 |a Interleukin-2 receptor alpha 
650 4 |a Monoclonal antibody 
650 7 |a Antibodies, Monoclonal, Humanized  |2 NLM 
650 7 |a Antineoplastic Agents  |2 NLM 
650 7 |a Immunoglobulin G  |2 NLM 
650 7 |a Interleukin-2 Receptor alpha Subunit  |2 NLM 
650 7 |a Daclizumab  |2 NLM 
650 7 |a CUJ2MVI71Y  |2 NLM 
700 1 |a Janik, John E  |e verfasserin  |4 aut 
700 1 |a Stewart, Donn M  |e verfasserin  |4 aut 
700 1 |a Jaffe, Elaine S  |e verfasserin  |4 aut 
700 1 |a Stetler-Stevenson, Maryalice  |e verfasserin  |4 aut 
700 1 |a Shih, Joanna H  |e verfasserin  |4 aut 
700 1 |a Fleisher, Thomas A  |e verfasserin  |4 aut 
700 1 |a Turner, Maria  |e verfasserin  |4 aut 
700 1 |a Urquhart, Nicole E  |e verfasserin  |4 aut 
700 1 |a Wharfe, Gilian H  |e verfasserin  |4 aut 
700 1 |a Figg, William D  |e verfasserin  |4 aut 
700 1 |a Peer, Cody J  |e verfasserin  |4 aut 
700 1 |a Goldman, Carolyn K  |e verfasserin  |4 aut 
700 1 |a Waldmann, Thomas A  |e verfasserin  |4 aut 
700 1 |a Morris, John C  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 155(2014), 2 vom: 22. Dez., Seite 176-87  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:155  |g year:2014  |g number:2  |g day:22  |g month:12  |g pages:176-87 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2014.09.012  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 155  |j 2014  |e 2  |b 22  |c 12  |h 176-87